A Long-Term Treatment may Improve Cognition

Data for a five-year study and an ongoing trial revealed that long-term treatment with Zeposia (ozanimod) may stabilize or improve cognitive function among relapsing-remitting MS patients.

These findings were more pronounced among patients with greater brain volumes.

For more info: Long-term Zeposia May Help Cognitive Function in Patients, Data Show

This content is provided for your general education and information only. It does not necessarily reflect Belong’s views and opinions. Belong does not endorse or support any specific product, service, or treatment.

Belong.Life is a leading global tech provider of high-engagement patient communities and care platforms, supporting millions of patients worldwide.

Among Belong.Life’s brands are the world’s largest social and professional networks for cancer patients (Belong – Beating Cancer Together) and multiple sclerosis patients (BelongMS), as well as i-Belong, BelongIBD, BelongPSOCoronApp (select countries), and more.

Belong.Life’s mission is to improve quality of life and quality of care worldwide through technology, engagement, data, and AI.

Skip to content